Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q2 2025 value amounting to -$8.9 million.

  • Lifecore Biomedical, Inc. \De\'s Gains from Investment Securities fell 718114.75% to -$8.9 million in Q2 2025 from the same period last year, while for May 2025 it was -$7.8 million, marking a year-over-year decrease of 32538.29%. This contributed to the annual value of -$7.8 million for FY2025, which is 32538.29% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Gains from Investment Securities amounted to -$8.9 million in Q2 2025, which was down 718114.75% from -$1.6 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Gains from Investment Securities high stood at $2.1 million for Q4 2024, and its period low was -$8.9 million during Q2 2025.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Gains from Investment Securities averaged around -$1.0 million, with its median value being $55000.0 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 849200.0% in 2024, then plummeted by 718114.75% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Gains from Investment Securities (Quarter) stood at $84000.0 in 2021, then skyrocketed by 69.05% to $142000.0 in 2022, then crashed by 82.39% to $25000.0 in 2023, then soared by 8492.0% to $2.1 million in 2024, then tumbled by 513.55% to -$8.9 million in 2025.
  • Its Gains from Investment Securities was -$8.9 million in Q2 2025, compared to -$1.6 million in Q1 2025 and $2.1 million in Q4 2024.